Lexicon Pharmaceuticals (LXRX) 1.48 $LXRX
Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at:
Lexicon To Present At The 2014 Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Fri May 09, 6:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2014 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 13, 2014 at 1:00 PM PDT (4:00 PM EDT) in Las Vegas. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2014 First Quarter Financial Results
PR Newswire - Thu May 08, 5:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2014.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Irritable Bowel Syndrome - Pipeline Review, H1 2014: 29 Companies and 37 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqsgh4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - AltheRx Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Dainippon Sumitomo Pharma Co., Ltd. - Dong-A Socio Holdings Co Ltd - Drais Pharmaceuticals, Inc. - Furiex Pharmaceuticals, Inc. - GIcare Pharma Inc - Hanmi Pharmaceuticals, Co. Ltd. - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - MicroDose Therapeutx, Inc. - Ono Pharmaceutical Co., Ltd. - ProMetic Life Sciences Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - SK Chemicals Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Tioga Pharmaceuticals, Inc. - X-BODY BioSciences, Inc. - Yuhan Corporation Drug Profiles: - ramosetron - ibodutant - linaclotide - rifaximin - asimadoline - dexloxiglumide - eluxadoline - rifaximin - tenapanor - linaclotide - plecanatide - solabegron hydrochloride - elobixibat - ONO-2952 - LX-1033 - ASP-7147 - (mosapride Bacillus subtilis Streptococcas feacium) - DSP-6952 - SKI-3246 - SYN-010 - linaclotide - larazotide acetate - DA-6886 - YH-12852 - mexiletine hydrochloride - MDT-006 - RQ-00202730 - PBI-1737 - RQ-00310941 - GIC-1001 For more information visit http://www.researchandmarkets.com/research/tq...able_bowel
Arthritis - Pipeline Review, H1 2014 - Includes 38 Company and 68 Drug Profiles
M2 - Wed May 07, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sblwf/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AngioLab, Inc - Astellas Pharma Inc. - AstraZeneca PLC - Bone Medical Limited - Bristol-Myers Squibb Company - CSL Limited - CalciMedica, Inc. - Can-Fite BioPharma Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - Endocyte, Inc. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Lexicon Pharmaceuticals, Inc. - MEI Pharma, Inc. - NasVax Ltd. - Oscotec Inc. - PLx Pharma Inc. - SelectX Pharmaceuticals, Inc. - Sylentis S.A. - Taisho Pharmaceutical Co., Ltd. - Taiwan Liposome Company, Ltd. - Teva Pharmaceutical Industries Limited - TheraKine Ltd. - Viron Therapeutics, Inc. - WhanIn Pharmaceutical Co., Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/3sblwf/arthritis
Lexicon To Report First Quarter 2014 Financial Results On May 8, 2014
PR Newswire - Mon May 05, 6:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, will release its first quarter 2014 financial results on Thursday, May 8, 2014 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the first quarter 2014 at 11:00 a.m. Eastern Time on May 8, 2014.
Can Lexicon Pharmaceuticals Challenge Big Pharma?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
The biotech sector's notorious for the boom-or-bust potential of many of its stocks, and investors in Lexicon Pharmaceuticals have felt that pressure over the past year. In that time, Lexicon's shares have plummeted by more than 26%. While it's...
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - Analysis of 26 Drug Profiles & 15 Companies
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9qdck3/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Sun Pharmaceutical Industries Limited - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Otsuka Holdings Co., Ltd. - Amakem NV - High Point Pharmaceuticals, LLC Drug Profiles - tafluprost - (tafluprost timolol maleate) - tafluprost - latanoprostene bunod - latanoprost - latanoprost - trabodenoson - PF-655 - SYL-040012 - RO-5093151 - latanoprost - aganepag isopropyl - simenepag isopropyl - AL-54478 - AMA-0076 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - brimonidine tartrate - ATS-8535 - Small Molecule for Glaucoma - ATS-907 - ATS-8535 For more information visit http://www.researchandmarkets.com/research/9qdck3/openangle
This Week in Biotech: Diabetes Patients Chalk Up 2 Impressive Victories
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 2:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 1:05PM CDT
Nearly 26 million people in this country have diabetes, according to the Centers for Disease Control and Prevention. Statistics from research company PhRMA indicate another 79 million are showing symptoms of pre-diabetes . It's a disease with...
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
Encouraging Results from Lexicon Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:20PM CDT
Lexicon announced encouraging results from a phase II study on LX4211.
Goodrich Petroleum Announces Positive Well Data; Micron Technology gets BUY rating from The Street
ACCESSWIRE - Mon Apr 14, 11:38PM CDT
Goodrich Petroleum Corp. (NYSE: GDP) - For an in-depth report on Goodrich Petroleum Corp. follow: www.BullTrends.com/stockquote/GDP
Lexicon Pharmaceuticals Up 8.2%, Shares Break Through Resistance (LXRX)
Comtex SmarTrend(R) - Mon Apr 14, 10:10AM CDT
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's best performing low-priced stocks, up 8.2% to $1.72 on 2.4x average daily volume. Lexicon Pharmaceuticals has traded 3.2 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (8.2% to the Dow's 0.8%) and outperformed the S&P 500 (8.2% to the S&P's 1.0%) during today's trading.
Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia
Leo Sun, The Motley Fool - Motley Fool - Mon Apr 14, 8:13AM CDT
Let's take a quick look at three biotech stocks -- Lexicon Pharmaceuticals , Alimera Sciences , and Akebia Therapeutics -- which could all be lifted by positive headlines this Monday morning . Lexicon soars on positive top-line results for...
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:
Stock to Watch: Lexicon Pharmaceuticals Down 5.6% (LXRX)
Comtex SmarTrend(R) - Thu Apr 03, 12:45PM CDT
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's worst performing low-priced stocks, down 5.6% to $1.71 on 1.1x average daily volume. Thus far today, Lexicon Pharmaceuticals has traded 1.3 million shares, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-5.5% to the Dow's -0.1%) and underperformed the S&P 500 (-5.5% to the S&P's -0.2%) during today's trading.
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 01, 4:25PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with companies wallowing at 52-week lows, I...
Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned
M2 - Wed Mar 12, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmb6vx/mice_model_market) has announced the addition of the "Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. Over the years, the use of mice models has increased rapidly. Mice have become the animals of choice for preclinical research in academic institutions as well as in pharmaceutical and biotechnology industries. The market has seen many innovations in the last few years, as companies have introduced new models for studying diseases like cancer and AIDS. This report categorizes the market into two broad segments, namely, mice models and services. By type, the market comprises of inbred, outbred, knockout, conditioned/surgically modified, hybrid/congenic, and spontaneous mutant mice. The inbred mice segment holds the largest share of 58% of the mice model market in 2013. This high share of inbred mice is attributed to their ability to reproduce the same results in different laboratories over a period of time. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The breeding services market holds the largest share of the services market and is expected to grow at the highest CAGR of 15% from 2013 to 2018, to reach $521 million by 2018. The mice care products market is categorized into cages, bedding, feed, and others. The caging market accounts for the largest share of the mice care products market, growing at a CAGR of 2.8% from 2013 to 2018 to reach $67.1 million in 2018. High investments and grants, which are leading to rising innovations in mice models, is a key factor that is likely to drive the growth of this market. In addition, the increase in the number of R&D activities in pharmaceutical industries, which are the prime users of mice models, is also responsible for driving this market. Furthermore, the high genetic similarity between mice and humans is another factor that is driving the use of mice models, globally. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/lm...del_market
Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at:
Lexicon To Present At The 2014 Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Fri May 09, 6:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2014 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 13, 2014 at 1:00 PM PDT (4:00 PM EDT) in Las Vegas. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2014 First Quarter Financial Results
PR Newswire - Thu May 08, 5:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2014.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Irritable Bowel Syndrome - Pipeline Review, H1 2014: 29 Companies and 37 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqsgh4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - AltheRx Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Dainippon Sumitomo Pharma Co., Ltd. - Dong-A Socio Holdings Co Ltd - Drais Pharmaceuticals, Inc. - Furiex Pharmaceuticals, Inc. - GIcare Pharma Inc - Hanmi Pharmaceuticals, Co. Ltd. - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - MicroDose Therapeutx, Inc. - Ono Pharmaceutical Co., Ltd. - ProMetic Life Sciences Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - SK Chemicals Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Tioga Pharmaceuticals, Inc. - X-BODY BioSciences, Inc. - Yuhan Corporation Drug Profiles: - ramosetron - ibodutant - linaclotide - rifaximin - asimadoline - dexloxiglumide - eluxadoline - rifaximin - tenapanor - linaclotide - plecanatide - solabegron hydrochloride - elobixibat - ONO-2952 - LX-1033 - ASP-7147 - (mosapride Bacillus subtilis Streptococcas feacium) - DSP-6952 - SKI-3246 - SYN-010 - linaclotide - larazotide acetate - DA-6886 - YH-12852 - mexiletine hydrochloride - MDT-006 - RQ-00202730 - PBI-1737 - RQ-00310941 - GIC-1001 For more information visit http://www.researchandmarkets.com/research/tq...able_bowel
Arthritis - Pipeline Review, H1 2014 - Includes 38 Company and 68 Drug Profiles
M2 - Wed May 07, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sblwf/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AngioLab, Inc - Astellas Pharma Inc. - AstraZeneca PLC - Bone Medical Limited - Bristol-Myers Squibb Company - CSL Limited - CalciMedica, Inc. - Can-Fite BioPharma Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - Endocyte, Inc. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Lexicon Pharmaceuticals, Inc. - MEI Pharma, Inc. - NasVax Ltd. - Oscotec Inc. - PLx Pharma Inc. - SelectX Pharmaceuticals, Inc. - Sylentis S.A. - Taisho Pharmaceutical Co., Ltd. - Taiwan Liposome Company, Ltd. - Teva Pharmaceutical Industries Limited - TheraKine Ltd. - Viron Therapeutics, Inc. - WhanIn Pharmaceutical Co., Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/3sblwf/arthritis
Lexicon To Report First Quarter 2014 Financial Results On May 8, 2014
PR Newswire - Mon May 05, 6:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, will release its first quarter 2014 financial results on Thursday, May 8, 2014 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the first quarter 2014 at 11:00 a.m. Eastern Time on May 8, 2014.
Can Lexicon Pharmaceuticals Challenge Big Pharma?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
The biotech sector's notorious for the boom-or-bust potential of many of its stocks, and investors in Lexicon Pharmaceuticals have felt that pressure over the past year. In that time, Lexicon's shares have plummeted by more than 26%. While it's...
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - Analysis of 26 Drug Profiles & 15 Companies
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9qdck3/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Sun Pharmaceutical Industries Limited - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Otsuka Holdings Co., Ltd. - Amakem NV - High Point Pharmaceuticals, LLC Drug Profiles - tafluprost - (tafluprost timolol maleate) - tafluprost - latanoprostene bunod - latanoprost - latanoprost - trabodenoson - PF-655 - SYL-040012 - RO-5093151 - latanoprost - aganepag isopropyl - simenepag isopropyl - AL-54478 - AMA-0076 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - brimonidine tartrate - ATS-8535 - Small Molecule for Glaucoma - ATS-907 - ATS-8535 For more information visit http://www.researchandmarkets.com/research/9qdck3/openangle
This Week in Biotech: Diabetes Patients Chalk Up 2 Impressive Victories
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 2:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 1:05PM CDT
Nearly 26 million people in this country have diabetes, according to the Centers for Disease Control and Prevention. Statistics from research company PhRMA indicate another 79 million are showing symptoms of pre-diabetes . It's a disease with...
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
Encouraging Results from Lexicon Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:20PM CDT
Lexicon announced encouraging results from a phase II study on LX4211.
Goodrich Petroleum Announces Positive Well Data; Micron Technology gets BUY rating from The Street
ACCESSWIRE - Mon Apr 14, 11:38PM CDT
Goodrich Petroleum Corp. (NYSE: GDP) - For an in-depth report on Goodrich Petroleum Corp. follow: www.BullTrends.com/stockquote/GDP
Lexicon Pharmaceuticals Up 8.2%, Shares Break Through Resistance (LXRX)
Comtex SmarTrend(R) - Mon Apr 14, 10:10AM CDT
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's best performing low-priced stocks, up 8.2% to $1.72 on 2.4x average daily volume. Lexicon Pharmaceuticals has traded 3.2 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (8.2% to the Dow's 0.8%) and outperformed the S&P 500 (8.2% to the S&P's 1.0%) during today's trading.
Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia
Leo Sun, The Motley Fool - Motley Fool - Mon Apr 14, 8:13AM CDT
Let's take a quick look at three biotech stocks -- Lexicon Pharmaceuticals , Alimera Sciences , and Akebia Therapeutics -- which could all be lifted by positive headlines this Monday morning . Lexicon soars on positive top-line results for...
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:
Stock to Watch: Lexicon Pharmaceuticals Down 5.6% (LXRX)
Comtex SmarTrend(R) - Thu Apr 03, 12:45PM CDT
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's worst performing low-priced stocks, down 5.6% to $1.71 on 1.1x average daily volume. Thus far today, Lexicon Pharmaceuticals has traded 1.3 million shares, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-5.5% to the Dow's -0.1%) and underperformed the S&P 500 (-5.5% to the S&P's -0.2%) during today's trading.
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 01, 4:25PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with companies wallowing at 52-week lows, I...
Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned
M2 - Wed Mar 12, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmb6vx/mice_model_market) has announced the addition of the "Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. Over the years, the use of mice models has increased rapidly. Mice have become the animals of choice for preclinical research in academic institutions as well as in pharmaceutical and biotechnology industries. The market has seen many innovations in the last few years, as companies have introduced new models for studying diseases like cancer and AIDS. This report categorizes the market into two broad segments, namely, mice models and services. By type, the market comprises of inbred, outbred, knockout, conditioned/surgically modified, hybrid/congenic, and spontaneous mutant mice. The inbred mice segment holds the largest share of 58% of the mice model market in 2013. This high share of inbred mice is attributed to their ability to reproduce the same results in different laboratories over a period of time. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The breeding services market holds the largest share of the services market and is expected to grow at the highest CAGR of 15% from 2013 to 2018, to reach $521 million by 2018. The mice care products market is categorized into cages, bedding, feed, and others. The caging market accounts for the largest share of the mice care products market, growing at a CAGR of 2.8% from 2013 to 2018 to reach $67.1 million in 2018. High investments and grants, which are leading to rising innovations in mice models, is a key factor that is likely to drive the growth of this market. In addition, the increase in the number of R&D activities in pharmaceutical industries, which are the prime users of mice models, is also responsible for driving this market. Furthermore, the high genetic similarity between mice and humans is another factor that is driving the use of mice models, globally. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/lm...del_market
